Cerebral Spurs Congress Plea for DEA ADHD Pill Probe
- Investigators call firm’s prescribing practices ‘manipulative’
- Panel chair urges DEA to pursue ‘bad actors’ in telehealth
Source: Cerebral
This article is for subscribers only.
Congressional investigators are asking the U.S. Drug Enforcement Administration what it’s doing to oversee mental health startups such as Cerebral Inc., calling the company’s business and prescribing practices “manipulative” and “aggressive,” according to a copy of a letter seen by Bloomberg.
In the letter, the chairman of a House Committee on Oversight and Government Reform subpanel asked the DEA about the startups, which have rapidly expanded by offering online consultation with clinicians as well as prescriptions for drugs such as Adderall and Xanax.